SeaBeLife Biotech

🗞️SeaBeLife in the News! We are proud to share the latest issue of Women in STEM from @Drug Target Review that features @Morgane Rousselot, our CEO and co-founder. Morgane shares her inspiring journey in STEM and the driving forces behind her dedicated work at SeaBeLife. “A combination of curiosity, passion for innovation and a drive to make a tangible impact in the world of biotechnology inspired me to pursue a career in STEM. From a young age, I was captivated by the intricacies of science and the potential it held for transforming lives. This fascination only deepened as I pursued my PhD in biochemistry, where I discovered how biology and chemistry can be used to address pressing healthcare challenges.” - Morgane Rousselot, CEO of SeaBeLife Biotech Under her leadership, SeaBeLife has raised €2.7M in the past twelve months alone to develop cutting-edge therapies to combat acute and severe diseases by blocking regulated necrosis. These advancements hold promise for multiple indications, including Age-related Macular Degeneration and Acute Kidney Injury. Read the full article here : https://lnkd.in/ex8p8ua9 #WomenInSTEM #STEM #Leadership #Biotech #CellDeath #AMD #AKI

💡 Exciting advancements in the field of regulated cell death have opened up new avenues for treating complex diseases. A recent article in Nature Portfolio’s Cell Death Discovery explores groundbreaking treatments targeting regulated cell death, specifically ferroptosis and necroptosis, two pivotal cell death pathways implicated in various medical conditions.   🧬Acute kidney injury (AKI) affects 13 million people worldwide annually. By targeting regulated cell death and modulating specific molecules, it's possible to prevent extensive tissue damage and improve patient recovery, offering promising new therapies where traditional treatments have often fallen short.   🔬 At SeaBeLife, we focus on manipulating these cell death pathways to reduce inflammation and cellular damage caused by ferroptosis and necroptosis. Our research aims to provide significant improvements for patients suffering from various acute and orphan diseases, including Acute Liver Injury and Failure (ALI/ALF), ischemia-reperfusion injury, AKI, age-related macular degeneration (AMD), and neurodegenerative diseases.   👉 Learn more about regulated cell death: https://lnkd.in/dAC3JUeS   #Biotech #CellDeath #Innovation #Healthcare

🗞️CHEManager International takes an in-depth look at SeaBeLife, explaining how we fight programmed cell death by developing first-in-class drugs designed to block regulated necrosis   "I see our key success drivers as being our innovative approach, our commitment to scientific excellence and our ability to address unmet clinical needs by focusing on the development of cutting-edge therapies for severe diseases such as ALI/ALF and dry AMD." - Morgane Rousselot, CEO of SeaBeLife Biotech    Read the full interview👇 https://lnkd.in/dgSDgz9K #biotech #necroptosis #ferroptosis #dryAMD

SeaBeLife is thrilled to announce its participation to the #EASLCongress 2024 in Milan, Italy! 🇮🇹 Join us from June 5-8 at Allianz MiCo, where we'll be presenting our groundbreaking in vivo results in a model of Drug-Induced Liver Injury (DILI) with our lead candidate, Sibiriline (SBL01), that stops regulated cell death. 📈 Our key findings: 🌟 Exceptional survival rates in preclinical models 🧬 Powerful combination of SBL01 and N-acetyl-cysteine (NAC) 🔬 Protective effects against cell necrosis Don’t miss our poster presentation to delve into these exciting developments and learn more about our commitment to pioneering new therapies for liver diseases. #LiverResearch #DrugDevelopment #Biotech EASL | The Home of Hepatology

📚 Dans 15 jours, c'est le bac de philo ! Et si c'était ce sujet qui tombait : 𝐿𝑎 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑖𝑒 𝑝𝑒𝑢𝑡-𝑒𝑙𝑙𝑒 𝑒̂𝑡𝑟𝑒 𝑢𝑛 𝑟𝑒𝑚𝑝𝑎𝑟𝑡 𝑐𝑜𝑛𝑡𝑟𝑒 𝑙𝑎 𝑓𝑎𝑡𝑎𝑙𝑖𝑡𝑒́ 𝑑𝑒 𝑙𝑎 𝑚𝑜𝑟𝑡 ? 🤔💀🛡️ Vous avez quatre heures ! ⏳ Ce sujet c'est un peu la question que nous pose SeaBeLife Biotech, cette pépite bretonne 🌊 dont la fondatrice dirigeante Morgane Rousselot se lance dans l'aventure du Prix de l’Entrepreneur EY. Cette startup tente de repousser les frontières de la science pour protéger la vie, là où elle commence : au cœur même de nos cellules. SeaBeLife Biotech est plus que jamais à l'avant-garde de la biotechnologie, avec une mission claire : sauver des vies en empêchant la mort régulée de nos cellules lorsqu'elles sont assaillies par des maladies graves. Leur technologie brevetée, issue de la riche biodiversité marine de #Roscoff, offre un espoir là où les alternatives thérapeutiques sont inexistantes ou insuffisantes. 🧬🌿 Grâce à des molécules testées "in vivo", qui bloquent simultanément la nécroptose et la ferroptose, SeaBeLife Biotech pourrait bien changer le cours de la médecine moderne sur certaines pathologies. Ces molécules sont le fruit de 10 ans de recherche et d'une collaboration étroite avec la Station Biologique de Roscoff. 🧪🔬 La vie est précieuse, et la protéger est un défi que SeaBeLife Biotech relève avec brio. Alors que les élèves de terminale se préparent à réfléchir sur les grandes questions de l'existence, Morgane Rousselot et son équipe travaillent sans relâche pour apporter des réponses concrètes et salvatrices. 📘✨ Un grand bravo à SeaBeLife Biotech pour leur travail remarquable et pour porter haut les couleurs de l'innovation bretonne dans le monde ! 👏🌍 Entretien réalisé avec la complicité de Eva DEMEURE et Julien du Boisgueheneuc et le suivi de toute notre Core Team #EOY régionale et nationale : Claire Delarbre Stanislas de Gastines Antoine Moittié 👉 Franck Sebag 👈 Johan Gaulin Emmanuelle Raveau WILLY ROCHER Marine Billant Audrey Vinès Maxime Gourlet Laura Pruja #EOYFR #EYOuest #entrepreneur #startup #scaleup #Innovation #Biotech #Santé #Bretagne #Philosophie

SeaBeLife is thrilled to announce its participation to the #EASLCongress 2024 in Milan, Italy! 🇮🇹 Join us from June 5-8 at Allianz MiCo, where we'll be presenting our groundbreaking in vivo results in a model of Drug-Induced Liver Injury (DILI) with our lead candidate, Sibiriline (SBL01), that stops regulated cell death. 📈 Our key findings: 🌟 Exceptional survival rates in preclinical models 🧬 Powerful combination of SBL01 and N-acetyl-cysteine (NAC) 🔬 Protective effects against cell necrosis Don’t miss our poster presentation to delve into these exciting developments and learn more about our commitment to pioneering new therapies for liver diseases. #LiverResearch #DrugDevelopment #Biotech EASL | The Home of Hepatology

🌍🏅 Europe’s Deeptech Meetup, l’évènement où les champions rencontrent des investisseurs européens.     🎤 Découvrez notre pitch vidéo pour en savoir plus sur notre startup et réserver bientôt un rdv one to one avec nous lors de l’évènement !  Vous trouverez toutes les informations concernant l’évènement en vous inscrivant directement sur le site : https://lnkd.in/eV_BvaxK    Europe's Deeptech Meetup – 23 mai 2024, de 14h30 à 21h - Paris Expo, 1 Pl. de la Porte de Versailles, Hall 3, 75015 Paris 👉 Les partenaires :  EuroQuity - Bpifrance Tudigo @francedeeptch @franceangels     #europedeeptechmeetup #earlystage #deeptech #investissement #investments 

🎉 The Top 30 of our 2024 #FemaleFounderChallenge is here! Our mission has been clear from the get go: boost women's presence in tech and increase their access to leadership roles and funding 💪 This initiative holds a special place in our hearts, as we're not just celebrating the accomplishments of these remarkable women; we're also drawing attention to the persistent gender gap within the industry. Let’s raise the bar together, cash is queen! 👑💰 A heartfelt thank you to our incredible partners, Mazars (Knowledge Partner & Sponsor), JCDecaux (Sponsor), IRIS (Knowledge Partner), Maddyness (Media Partner) and SISTAFUND (Ambassador). And a special thanks to Mazars & Iris for helping us with this selection 🧡

SeaBeLife is thrilled to announce that we've been selected as one of the 30 Most Promising Women-led Startups 2024 in Viva Technology ´s prestigious Female Founder Challenge! We are led by our CEO, Morgane Rousselot Rousselot, who has been instrumental in the development of our startup, this recognition from VivaTech is a testament to our dedication and impact in revolutionizing healthcare. At SeaBeLife, we aim to save lives threatened by untreatable diseases of major organs, including the liver, kidneys, heart, and brain, by using our unique patented technology to directly block programmed cell death. 💉🔬 Join us for the eighth edition of VivaTech from May 22nd to 25th, 2024, at Expo Porte de Versailles, Paris. Where business meets innovation, come explore disruptive topics in tech with world-premiere demos, launches, and conferences in a collaborative ecosystem. 🇫🇷 In the lead-up to VivaTech 2024, SeaBeLife will be taking part in the Fundraising Bootcamp, with sessions every Wednesday from April 10th to 24th, in partnership with SISTA and alongside all the other Challenge participants. During this bootcamp our team with delve in-depth into topics including business strategy, fundraising, and leadership. Check out the other startups here: https://lnkd.in/ewPn48zS #FemaleFounderChallenge #VivaTech2024 #Innovation #Award #Event #Biotech

We're thrilled to announce that SeaBeLife will be taking the stage and pitching at BioVaria 2024's Startup Pitch & Partner Program in Munich! 🚀🇩🇪   Join us on the first day of the event, April 29th, as SeaBeLife presents its innovative and unique technology that directly targets programmed cell death in vital organs such as the liver, kidneys, heart, and brain.   SeaBeLife is proud to participate in BioVaria 2024, a premier event that brings together innovators, investors, and industry leaders in the life sciences sector, fostering innovation and driving positive change in the field of biotechnology.   Are you attending BioVaria 2024? Don't miss out on the opportunity to learn more about SeaBeLife and connect with us during the event!💡   Learn more here: https://www.biovaria.org   #BioVaria #LifeSciences #Innovation #Healthtech #Biotech # #Healthcare